DACH Open-angle Glaucoma Market (2026 - 2033)

DACH Open-angle Glaucoma Market Summary

The DACH open-angle glaucoma market size was valued at USD 53.2 million in 2025 and is projected to grow from USD 56.7 million in 2026 to USD  91.8 million by 2033, at a CAGR of 7.1% from 2026 to 2033. The rapidly aging population across the DACH region is one of the primary factors driving the increasing prevalence of open-angle glaucoma (OAG). As a chronic age-related optic neuropathy, primary open-angle glaucoma (POAG) predominantly affects older adults, with disease incidence and prevalence increasing substantially after the age of 60.

The demographic transition toward an older population across the DACH (Germany, Austria, and Switzerland) countries is therefore expanding the number of individuals at risk of developing glaucoma, creating sustained demand for early diagnosis, long-term disease management, and advanced glaucoma treatment technologies. Germany, Austria, and Switzerland are countries with the highest life expectancy and a steadily growing elderly population. Improvements in healthcare infrastructure, disease prevention, and overall living standards have contributed to increased longevity, resulting in a larger proportion of individuals aged 65 years and older. While these demographic changes reflect positive healthcare outcomes, they also contribute to a growing burden of chronic ophthalmic disorders, particularly glaucoma, which remains one of the leading causes of irreversible blindness among older adults. Consequently, healthcare providers across the DACH region are witnessing a gradual increase in glaucoma-related outpatient consultations, diagnostic evaluations, and long-term follow-up requirements.

The aging demographic also supports higher utilization of ophthalmology services throughout the region. Older adults are more likely to undergo routine comprehensive eye examinations, optical coherence tomography (OCT), visual field testing, optic nerve imaging, and intraocular pressure monitoring, leading to improved identification of glaucoma cases. As awareness of preventive eye care continues to increase and healthcare systems emphasize early detection of vision-threatening diseases, demand for glaucoma screening and diagnostic services is expected to rise steadily across the region.

Glaucoma societies across the DACH region play a central role in advancing clinical practice, research collaboration, and awareness related to open-angle glaucoma. Regional and national organizations support the development of standardized treatment guidelines, promote continuing medical education, and facilitate knowledge exchange among ophthalmologists. These societies also contribute to early detection initiatives, patient education programs, and advocacy efforts aimed at reducing glaucoma-related vision loss. In addition, they often collaborate with healthcare institutions, regulatory bodies, and industry stakeholders to encourage the adoption of advanced diagnostic and therapeutic approaches.

Glaucoma Societies

Technological innovation is also playing a crucial role in expanding MIGS adoption. Continuous advancements in micro-stent design, implant materials, and delivery systems have improved procedural outcomes and broadened the range of available treatment options. These innovations are enabling more precise control of intraocular pressure and better long-term disease management. Furthermore, MIGS devices are increasingly being used alongside pharmacological therapies and laser treatments, creating a more comprehensive and patient-centric treatment approach.

Finally, the rising prevalence of glaucoma and the need for long-term disease management are reinforcing the shift toward minimally invasive procedures. As healthcare systems in DACH aim to reduce surgical complications, hospital stays, and overall treatment burden, MIGS offers a cost-effective and efficient alternative to traditional surgeries. Its ability to be performed in outpatient settings or combined with other ophthalmic procedures further enhances its appeal, positioning minimally invasive glaucoma surgery as a key growth driver within the DACH open-angle glaucoma market.

The expansion of artificial intelligence (AI)-based glaucoma screening and early diagnosis programs presents a significant opportunity for the DACH Open-Angle Glaucoma (OAG) market. AI-powered diagnostic platforms integrated with fundus photography, optical coherence tomography (OCT), and tele ophthalmology can improve the accuracy and efficiency of large-scale glaucoma screening, enabling earlier diagnosis and timely initiation of treatment. These technologies also help address workforce shortages by supporting ophthalmologists and optometrists in high-volume screening settings while reducing diagnostic variability.

Market Dynamics

The DACH open-angle glaucoma market is witnessing steady growth as hospitals, university eye clinics, ambulatory surgical centers (ASCs), and specialized ophthalmology practices increasingly adopt advanced diagnostic technologies and minimally invasive glaucoma surgery (MIGS) solutions to address the rising burden of glaucoma and preserve long-term vision. The market encompasses a wide range of products and services, including intraocular pressure (IOP)-lowering pharmaceuticals, laser therapies, minimally invasive glaucoma implants, conventional glaucoma surgical devices, diagnostic imaging systems, visual field analyzers, and ophthalmic monitoring solutions designed to improve disease detection, treatment outcomes, and patient quality of life. The growing prevalence of primary open-angle glaucoma (POAG), driven by the aging population across Germany, Austria, and Switzerland, is a major factor supporting market growth. Increasing awareness regarding early diagnosis through routine ophthalmic screening, along with favorable adoption of optical coherence tomography (OCT), tonometry, gonioscopy, and visual field testing, is enabling earlier disease detection and more effective clinical management.

Market Concentration & Characteristics

The DACH open-angle glaucoma industry is moderately consolidated, with major companies such as AbbVie Inc., Alcon Inc., Santen Pharmaceutical Co., Ltd., and MicroSurgical Technology holding significant positions across the glaucoma treatment and surgical device landscape. These companies offer a comprehensive portfolio of glaucoma management solutions, including intraocular pressure (IOP)-lowering pharmaceuticals, minimally invasive glaucoma surgery (MIGS) devices, glaucoma drainage implants, laser treatment technologies, and ophthalmic surgical instruments designed to support the management of mild, moderate, and advanced open-angle glaucoma. Their product portfolios address the full continuum of glaucoma care, from early-stage medical management to laser trabeculoplasty, minimally invasive surgical interventions, and conventional filtration procedures for patients with uncontrolled intraocular pressure. In addition, leading manufacturers continue to invest in research and development focused on next-generation MIGS technologies, sustained drug-delivery systems, advanced glaucoma drainage devices, digital ophthalmology solutions, and artificial intelligence-assisted diagnostic platforms.

The DACH open-angle glaucoma market is witnessing a high degree of innovation driven by the increasing demand for advanced diagnostic technologies, minimally invasive glaucoma surgery (MIGS), sustained drug-delivery systems, and digital ophthalmology solutions that improve intraocular pressure (IOP) control, preserve visual function, and reduce the long-term treatment burden for patients. For instance, in September, Alcon announced at the European Society of Cataract and Refractive Surgeons (ESCRS) Congress the expansion of its glaucoma innovations portfolio, with a strong focus on the Hydrus Microstent supported by new and long-term clinical data. In addition, the Hydrus Microstent, a minimally invasive glaucoma surgery (MIGS) device, was highlighted for its ability to lower intraocular pressure in open-angle glaucoma patients by enhancing aqueous outflow through Schlemm’s canal when implanted alongside cataract surgery.

The DACH open-angle glaucoma industry is witnessing a significant increase in partnerships and collaborations among pharmaceutical companies, ophthalmic device manufacturers, diagnostic technology providers, academic research institutions, and healthcare organizations to accelerate innovation, improve early disease detection, and enhance long-term glaucoma management. These strategic collaborations are focused on developing next-generation minimally invasive glaucoma surgery (MIGS) technologies, artificial intelligence (AI)-enabled diagnostic platforms, digital ophthalmology solutions, and novel therapeutic approaches to improve patient outcomes while expanding access to advanced glaucoma care across DACH.

The market operates within a highly regulated framework governed by the European Medicines Agency (EMA), the European Commission under the Medical Device Regulation (EU MDR 2017/745), and national regulatory authorities, including the Federal Institute for Drugs and Medical Devices (BfArM) and Paul Ehrlich Institute (PEI) in Germany, AGES (Austrian Agency for Health and Food Safety) in Austria, and Swissmedic in Switzerland. These regulatory bodies oversee the safety, efficacy, quality, and clinical performance of glaucoma pharmaceuticals, minimally invasive glaucoma surgery (MIGS) devices, glaucoma drainage implants, ophthalmic lasers, diagnostic imaging systems, and digital ophthalmology solutions used in the diagnosis and management of open-angle glaucoma.

The DACH open-angle glaucoma industry faces moderate competition from a range of alternative treatment approaches, including generic intraocular pressure (IOP)-lowering medications, laser-based therapies, conventional glaucoma surgeries, and conservative disease management strategies that may reduce the adoption of premium pharmaceuticals and advanced minimally invasive glaucoma surgery (MIGS) devices. Generic prostaglandin analogs, beta-blockers, carbonic anhydrase inhibitors, alpha agonists, and fixed-dose combination eye drops remain widely prescribed as first-line therapies due to their established clinical efficacy, broad reimbursement coverage, and relatively low treatment costs, particularly among patients with early-stage disease.

The DACH open-angle glaucoma market is witnessing significant regional expansion as ophthalmic pharmaceutical companies, glaucoma device manufacturers, and diagnostic technology providers strengthen their presence across Germany, Austria, and Switzerland through product launches, regulatory approvals, commercial expansion, and broader access to advanced glaucoma care. Growing investments in minimally invasive glaucoma surgery (MIGS), digital ophthalmology platforms, and next-generation diagnostic technologies are enabling healthcare providers to improve early diagnosis, optimize intraocular pressure (IOP) management, and expand treatment options for patients with open-angle glaucoma across the region.

Analyst Perspective

The DACH open-angle glaucoma market has emerged as one of the most important segments within the regional ophthalmology and vision care industry, driven by the growing burden of age-related eye diseases, increasing prevalence of primary open-angle glaucoma (POAG), expanding elderly population, and continuous advancements in glaucoma diagnostics and minimally invasive surgical technologies. Open-angle glaucoma management has evolved from a treatment approach primarily dependent on topical medications toward a comprehensive disease management pathway that integrates early diagnosis, precision monitoring, laser therapies, sustained drug delivery systems, and minimally invasive glaucoma surgery (MIGS). As healthcare systems across Germany, Austria, and Switzerland increasingly prioritize early intervention to prevent irreversible vision loss, advanced glaucoma treatment technologies are becoming an integral component of routine ophthalmic care.

Product Insights

The Schlemm’s canal-based devices segment dominated the market, accounting for the largest share of 62.3% in 2025, and is expected to witness the fastest CAGR of 7.5% over the forecast period. Schlemm’s canal-based devices represent a critical segment within the DACH open-angle glaucoma market, driven by the growing adoption of minimally invasive glaucoma surgery (MIGS). These devices are designed to restore physiological aqueous humor outflow by targeting the Schlemm’s canal, which plays a central role in intraocular pressure (IOP) regulation. Dysfunction in this canal is a primary contributor to glaucoma progression, particularly in open-angle glaucoma cases. The increasing preference for safer, less invasive procedures has accelerated the adoption of Schlemm’s canal-based technologies across the region. MIGS devices targeting this canal improve fluid drainage by bypassing or dilating the trabecular meshwork, offering effective IOP reduction with fewer complications compared to traditional filtration surgeries. This aligns with broader clinical trends favoring faster recovery times, reduced surgical risks, and improved patient outcomes.

The subconjunctival devices segment is expected to witness growth at a significant CAGR over the forecast period. Subconjunctival devices represent a critical segment within the DACH open-angle glaucoma market, particularly for patients requiring more aggressive intraocular pressure (IOP) reduction than angle-based or Schlemm’s canal procedures can provide. These devices function by creating an alternative drainage pathway, diverting aqueous humor from the anterior chamber to the subconjunctival space, forming a controlled filtration bleb. This mechanism closely resembles traditional trabeculectomy, but with a more standardized and minimally invasive approach. Subconjunctival MIGS (minimally invasive glaucoma surgery) devices are gaining traction in the market due to their ability to deliver significant IOP reduction, making them suitable for moderate-to-severe glaucoma cases or patients inadequately controlled with medications or other MIGS techniques. Notable devices include the XEN Gel Stent and the PreserFlo MicroShunt, both of which are widely adopted across DACH ophthalmology centers.

Procedure Insights

The non-bleb-based procedures segment dominated the DACH open angle glaucoma industry, accounting for the largest revenue share in 2025, and is expected to witness the fastest CAGR over the forecast period. The increasing preference for these procedures is primarily driven by their favorable safety profile, reduced postoperative complications, faster visual recovery, and growing adoption of minimally invasive glaucoma surgery (MIGS) techniques across Germany, Austria, and Switzerland. Unlike traditional filtering surgeries that create a subconjunctival bleb, non-bleb-based procedures enhance the eye's natural aqueous humor outflow pathways, minimizing the risk of bleb-related infections, hypotony, bleb leaks, and long-term postoperative management. The region has witnessed increasing adoption of trabecular and Schlemm's canal-based MIGS procedures, particularly among patients with mild-to-moderate primary open-angle glaucoma (POAG). The preference for tissue-sparing procedures aligns with the growing emphasis on improving patient outcomes while minimizing surgical risk. These factors contribute to the growth of the segment.

The bleb-based procedures segment is expected to grow at the second-fastest CAGR over the forecast period. Bleb-based procedures encompassing traditional trabeculectomy and a newer generation of minimally invasive bleb-involving surgeries (MIBS) remain a cornerstone of surgical management for open-angle glaucoma (OAG) across DACH, particularly as the disease burden continues to rise alongside an aging population. In addition to conventional trabeculectomy, the adoption of minimally invasive bleb surgery (MIBS) is steadily increasing across the DACH region. Procedures involving subconjunctival filtration devices are gaining acceptance among glaucoma specialists because they combine the pressure-lowering effectiveness of filtration surgery with a less invasive surgical approach. These factors collectively contribute to the growth of the segment.

Type Insights

The standalone dominated the DACH open angle glaucoma market, accounting for the largest revenue share in 2025. Standalone procedures represent a major segment of the DACH open-angle glaucoma (oag) procedures market, encompassing both bleb-based and non-bleb-based surgical approaches performed independently without concurrent cataract surgery. These procedures are indicated for patients whose intraocular pressure (IOP) remains inadequately controlled despite medications or laser therapy and who require surgical intervention to slow disease progression. The choice between standalone bleb-based and non-bleb-based procedures depends on factors such as glaucoma severity, target IOP, patient age, ocular anatomy, previous surgeries, and the surgeon's clinical assessment. While bleb-based procedures are generally preferred for patients requiring substantial and sustained IOP reduction, non-bleb-based procedures are increasingly adopted for patients with mild to moderate disease due to their favorable safety profile and preservation of the eye's natural drainage pathways.

The combined segment is expected to grow at the fastest CAGR over the forecast period. Combined procedure type involving the simultaneous performance of glaucoma surgery and cataract surgery (phacoemulsification) during a single operative session. Both bleb-based and non-bleb-based glaucoma procedures can be performed in combination with cataract extraction, allowing ophthalmic surgeons to manage elevated intraocular pressure (IOP) while restoring visual acuity affected by cataracts. Combined procedures are particularly beneficial for patients diagnosed with coexisting cataracts and open-angle glaucoma, reducing the need for multiple surgeries, shortening recovery time, and improving overall patient convenience.

Edn Use Insights

The inpatient segment dominated the DACH open angle glaucoma industry in 2025. Inpatient care is particularly critical for higher-complexity OAG procedures. Ophthalmic surgeries are commonly performed by well-trained surgical teams in inpatient hospital settings. Hospitals provide a controlled, sterile environment highly conducive to such surgeries, with surgeons, anesthesiologists, nurses, and other specialists collaborating to ensure safe execution. Hospitals are also equipped to handle potential complications and offer comprehensive postoperative care. For procedures such as trabeculectomy with antimetabolites, Baerveldt or Ahmed glaucoma valve implantation, and non-penetrating deep sclerectomy, all commonly performed across major DACH academic centers, inpatient admission allows for the close postoperative monitoring these surgeries demand.

The outpatient segmentis anticipated to grow at a significant rate over the forecast period. The DACH open angle glaucoma market is witnessing a significant shift towards outpatient and ambulatory surgical centers for ophthalmic procedures, improving accessibility and cost-efficiency, further supported by rising public awareness about eye health and government initiatives promoting preventive care. This shift is not incidental; it is structurally enabled by the rise of MIGS and laser-based procedures, which require no overnight admission, carry minimal risk of complications, and allow patients to resume normal activities within days.

Country Insights

The DACH open angle glaucoma market is experiencing strong growth due to the rising prevalence of glaucoma associated with an aging population, increasing awareness of early diagnosis, and continuous advancements in ophthalmic technologies. Growing adoption of minimally invasive glaucoma surgery (MIGS), sustained innovation in glaucoma drainage devices and drug delivery systems, and wider availability of advanced diagnostic modalities such as optical coherence tomography (OCT) and visual field imaging are improving disease detection and treatment outcomes across Germany, Austria, and Switzerland. In addition, well-established healthcare infrastructure, favorable access to specialized ophthalmology services, ongoing clinical research, and increasing investments by leading pharmaceutical and medical device companies are accelerating the adoption of innovative glaucoma therapies. Rising healthcare expenditure, expanding physician training programs, and the growing emphasis on preserving vision and improving patients' quality of life are further supporting market expansion, positioning the DACH region as one of Europe's leading markets for advanced open-angle glaucoma diagnosis and management.

Germany Open-angle Glaucoma Market Trends

The Germany open angle glaucoma market is experiencing steady growth, underpinned by a high disease burden, an advanced healthcare infrastructure, strong national health insurance coverage, and a deeply embedded culture of evidence-based ophthalmological practice. The country's role as both a major clinical research hub and a high-volume surgical center places it at the center of DACH OAG treatment innovation. The prevalence of glaucoma in the German adult population above 40 years of age is currently 2.1%, resulting in approximately 980,000 individuals with glaucoma, plus at least one additional million subjects with ocular hypertension (OHT), with two-thirds of all glaucoma cases occurring in those above 70 years of age. Drawing on Germany's largest public health insurance dataset, the age-standardized prevalence of POAG in adults aged 50 and over was 2.79%, with an age-standardized incidence rate of 0.38 per 100 person-years with sex differences significant for both prevalence and incidence, showing higher rates in women compared to men.

Austria Open-angle Glaucoma Market Trends

The open angle glaucoma market in Austria is expected to grow significantly over the forecast period. The growth is supported by increasing disease prevalence, rising life expectancy, and stronger awareness regarding preventable blindness. Primary open-angle glaucoma (POAG) is the most common form of glaucoma and represents a significant ophthalmic burden because the disease progresses slowly and often remains undiagnosed until irreversible vision damage occurs. Studies from the Salzburg-Moorfields Collaborative Glaucoma Study, one of Austria’s major glaucoma screening initiatives, projected a substantial increase in glaucoma cases in the country between 2001 and 2031 due to demographic aging trends. The study highlighted that Austria’s growing elderly population would significantly expand the number of patients requiring long-term glaucoma monitoring and treatment.

Switzerland Open-angle Glaucoma Market Trends

The Switzerland open angle glaucoma market is experiencing lucrative growth. The growth is primarily driven by the country's aging population and the increasing prevalence of age-related ophthalmic disorders. Glaucoma predominantly affects older adults, and Switzerland's steadily expanding elderly population is expected to significantly increase the number of patients requiring long-term disease management. Glaucoma remains one of the leading causes of blindness in Switzerland, affecting approximately 2% of individuals aged 40 years and older. According to estimates from the Swiss Ophthalmological Society (SOG), around 100,000 people in Switzerland are living with glaucoma, including nearly 50,000 patients with elevated intraocular pressure-related glaucoma, of whom approximately 10% are at risk of blindness. In addition, normal-tension glaucoma accounts for an estimated 30–45% of all glaucoma cases, further highlighting the significant disease burden in the country.

Key DACH Open-angle Glaucoma Company Insights

The DACH open-angle glaucoma market is highly competitive, with leading companies focusing on strengthening their market positions through continuous product innovation, strategic collaborations, regulatory approvals, portfolio expansion, and regional commercialization initiatives. Manufacturers are increasingly investing in advanced glaucoma treatment technologies, including minimally invasive glaucoma surgery (MIGS) devices, sustained drug-delivery systems, glaucoma drainage implants, ophthalmic lasers, artificial intelligence-enabled diagnostic platforms, and digital ophthalmology solutions to improve intraocular pressure (IOP) control, enable earlier disease detection, and enhance long-term visual outcomes.

Key DACH Open-angle Glaucoma Companies

The following key companies have been profiled for this study of the DACH open angle glaucoma market.

• AbbVie Inc.

• Santen Pharmaceutical Co., Ltd.

• Glaukos Corporation

• Alcon Inc.

• Sight Sciences, Inc.

• MicroSurgical Technology

• New World Medical

Competitive Benchmarking

Recent Development

• Alcon announced at the European Society of Cataract and Refractive Surgeons (ESCRS) Congress the expansion of its glaucoma innovations portfolio, with a strong focus on the Hydrus Microstent supported by new and long-term clinical data. In addition, the Hydrus Microstent, a minimally invasive glaucoma surgery (MIGS) device, was highlighted for its ability to lower intraocular pressure in open-angle glaucoma patients by enhancing aqueous outflow through Schlemm’s canal when implanted alongside cataract surgery.

DACH Open-angle Glaucoma Market Report Scope

DACH Open-angle Glaucoma Market Report Segmentation

This report forecasts revenue & volume growth at the regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. Forthis study, Grand View Research has segmented the DACH open-angle glaucoma market report based on product, procedure, type, end use, and country:

• Product Outlook (Volume, Units; Revenue, USD Million, 2021 - 2033)

  • Schlemm’s Canal-Based Devices

  • Subconjunctival Devices

• Procedure Outlook (Volume, Units; Revenue, USD Million, 2021 - 2033)

  • Bleb-based Procedure

    • Perforating (Fistulizing) Bleb-based Procedures

    • Non-Perforating Bleb-based Procedures (NPDS)

  • Non-bleb-based Procedure

• Type Outlook (Volume, Units; Revenue, USD Million, 2021 - 2033)

  • Standalone

  • Combined

• End Use Outlook (Volume, Units; Revenue, USD Million, 2021 - 2033)

  • Inpatient

  • Outpatient

• Country Outlook (Volume, Units; Revenue, USD Million, 2021 - 2033)

  • Germany

  • Austria

  • Switzerland

Research Methodology

The DACH open-angle glaucoma market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each DACH open-angle glaucoma segment quantified using the revenue-capture definitions in the table below.

Segment Definition

Estimation Model

Delivered Customizations

This report has been delivered with the following In-depth customizations